Main text Alzheimer’s disease(AD),the most prevalent form of dementia,is characterized by deposits of two abnormal proteins,namely amyloid-β(Aβ)and tau,in the brain.There is growing evidence for the clinical signif...Main text Alzheimer’s disease(AD),the most prevalent form of dementia,is characterized by deposits of two abnormal proteins,namely amyloid-β(Aβ)and tau,in the brain.There is growing evidence for the clinical significance of plasma phosphorylated tau(p-tau)assays in detecting AD pathology[1,2],similar to CSF and positron emission tomography(PET)biomarkers.Currently available immunoassays for plasma p-tau detect C-terminally truncated p-tau containing the N-terminus to the mid-domain(N-p-tau)[2].展开更多
基金supported in part by AMED under Grant Numbers JP18dm0207018,JP19dm0207072,JP18dk0207026,JP19dk0207049,21wm0425015,21dm0307003,22dk0207055MEXT KAKENHI under Grant Numbers JP16H05324 and JP18K07543+1 种基金JST under Grant Numbers JPMJCR1652 and JPMJMS2024the Kao Research Council for the Study of Healthcare Science,Biogen Idec Inc.and APRINOIA Therapeutics.
文摘Main text Alzheimer’s disease(AD),the most prevalent form of dementia,is characterized by deposits of two abnormal proteins,namely amyloid-β(Aβ)and tau,in the brain.There is growing evidence for the clinical significance of plasma phosphorylated tau(p-tau)assays in detecting AD pathology[1,2],similar to CSF and positron emission tomography(PET)biomarkers.Currently available immunoassays for plasma p-tau detect C-terminally truncated p-tau containing the N-terminus to the mid-domain(N-p-tau)[2].
